Skip to content
Flyout Menu
  • About Us
    • Overview
    • The Sai Way
    • Leadership
    • Quality
    • Facilities
      • Boston
      • Manchester
      • Hyderabad
      • Bidar
  • Our Capabilities
    • Discovery
      • CADD & Structural Biology
      • Compound Management
      • DMPK (Drug Metabolism & Pharmacokinetics)
      • In Vitro Biology
      • In Vivo Pharmacology
      • Integrated Drug Discovery (IDD)
      • Safety & Toxicology
      • Synthetic & Medicinal Chemistry
    • Drug Substance Development
      • Analytical Development
      • Developability & Pre-Formulation
      • Particle Science & Engineering
      • Process Development
      • Process Engineering
      • Discovery Process Chemistry
    • Drug Substance Manufacturing
      • Engineering Technologies
      • Infrastructure
      • Product Types
    • New Modalities
      • Antibody–Drug Conjugates
      • Lipids
      • Oligos
      • Peptides
    • Formulations
      • Clinical Formulation Supplies
      • New Chemical Entity (NCE) formulation development
  • Responsibility
    • Sustainability
    • Health, Safety and Environment
    • Corporate Social Responsibility
  • Knowledge Hub
    • Newsroom
    • Newsroom – Blogs
    • Newsroom – Case Studies
  • Investors
    • Financial Information
    • Annual reports
    • Corporate Governance
    • Shareholder Services
    • Disclosures
  • Careers
  • Contact us
  • About Us
    • Overview
    • The Sai Way
    • Leadership
    • Quality
    • Facilities
    • – Boston
    • – Manchester
    • – Hyderabad
    • – Bidar
    • Overview
    • The Sai Way
    • Leadership
    • Quality
    • Facilities
    • – Boston
    • – Manchester
    • – Hyderabad
    • – Bidar
  • Our Capabilities
    • Discovery
    • Integrated Drug Discovery (IDD)
    • CADD & Structural Biology
    • Synthetic & Medicinal Chemistry
    • In Vitro Biology
    • DMPK (Drug Metabolism & Pharmacokinetics)
    • In Vivo Pharmacology
    • Safety & Toxicology
    • Compound Management
    • Discovery
    • Integrated Drug Discovery (IDD)
    • CADD & Structural Biology
    • Synthetic & Medicinal Chemistry
    • In Vitro Biology
    • DMPK (Drug Metabolism & Pharmacokinetics)
    • In Vivo Pharmacology
    • Safety & Toxicology
    • Compound Management
    • Drug Substance Development
    • Discovery Process Chemistry
    • Process Development
    • Analytical Development
    • Process Engineering
    • Particle Science & Engineering
    • Developability & Pre-Formulation
    • Drug Substance Development
    • Discovery Process Chemistry
    • Process Development
    • Analytical Development
    • Process Engineering
    • Particle Science & Engineering
    • Developability & Pre-Formulation
    • Drug Substance Manufacturing
    • Product Types
    • Infrastructure
    • Engineering Technologies
    • Formulations
    • New Chemical Entity (NCE) formulation development
    • Clinical Formulation Supplies
    • Drug Substance Manufacturing
    • Product Types
    • Infrastructure
    • Engineering Technologies
    • Formulations
    • New Chemical Entity (NCE) formulation development
    • Clinical Formulation Supplies
    • New Modalities
    • Antibody–Drug Conjugates
    • Peptides
    • Oligos
    • New Modalities
    • Antibody–Drug Conjugates
    • Peptides
    • Oligos
  • Responsibility
    • Sustainability
    • Health, Safety and Environment
    • Corporate Social Responsibility
    • Sustainability
    • Health, Safety and Environment
    • Corporate Social Responsibility
  • Knowledge Hub
    • Newsroom
    • Blogs
    • Case Studies
    • Newsroom
    • Blogs
    • Case Studies
  • Investors
    • Investor Relations
    • Financial Information
    • Annual reports
    • Corporate Governance
    • Shareholder Services
    • Disclosures
    • Investor Relations
    • Financial Information
    • Annual reports
    • Corporate Governance
    • Shareholder Services
    • Disclosures
  • Careers
  • Contact us
  • About Us
    • Overview
    • The Sai Way
    • Leadership
    • Quality
    • Facilities
    • – Boston
    • – Manchester
    • – Hyderabad
    • – Bidar
    • Overview
    • The Sai Way
    • Leadership
    • Quality
    • Facilities
    • – Boston
    • – Manchester
    • – Hyderabad
    • – Bidar
  • Our Capabilities
    • Discovery
    • Integrated Drug Discovery (IDD)
    • CADD & Structural Biology
    • Synthetic & Medicinal Chemistry
    • In Vitro Biology
    • DMPK (Drug Metabolism & Pharmacokinetics)
    • In Vivo Pharmacology
    • Safety & Toxicology
    • Compound Management
    • Discovery
    • Integrated Drug Discovery (IDD)
    • CADD & Structural Biology
    • Synthetic & Medicinal Chemistry
    • In Vitro Biology
    • DMPK (Drug Metabolism & Pharmacokinetics)
    • In Vivo Pharmacology
    • Safety & Toxicology
    • Compound Management
    • Drug Substance Development
    • Discovery Process Chemistry
    • Process Development
    • Analytical Development
    • Process Engineering
    • Particle Science & Engineering
    • Developability & Pre-Formulation
    • Drug Substance Development
    • Discovery Process Chemistry
    • Process Development
    • Analytical Development
    • Process Engineering
    • Particle Science & Engineering
    • Developability & Pre-Formulation
    • Drug Substance Manufacturing
    • Product Types
    • Infrastructure
    • Engineering Technologies
    • Formulations
    • New Chemical Entity (NCE) formulation development
    • Clinical Formulation Supplies
    • Drug Substance Manufacturing
    • Product Types
    • Infrastructure
    • Engineering Technologies
    • Formulations
    • New Chemical Entity (NCE) formulation development
    • Clinical Formulation Supplies
    • New Modalities
    • Antibody–Drug Conjugates
    • Peptides
    • Oligos
    • New Modalities
    • Antibody–Drug Conjugates
    • Peptides
    • Oligos
  • Responsibility
    • Sustainability
    • Health, Safety and Environment
    • Corporate Social Responsibility
    • Sustainability
    • Health, Safety and Environment
    • Corporate Social Responsibility
  • Knowledge Hub
    • Newsroom
    • Blogs
    • Case Studies
    • Newsroom
    • Blogs
    • Case Studies
  • Investors
    • Investor Relations
    • Financial Information
    • Annual reports
    • Corporate Governance
    • Shareholder Services
    • Disclosures
    • Investor Relations
    • Financial Information
    • Annual reports
    • Corporate Governance
    • Shareholder Services
    • Disclosures
  • Careers
  • Contact us
  • About Us
    Main Menu
    • Overview
    • The Sai Way
    • Leadership
    • Quality
    • Facilities
      • Boston
      • Manchester
      • Hyderabad
      • Bidar
  • Our Capabilities
    Main Menu
    • Discovery
      • Integrated Drug Discovery (IDD)
      • CADD & Structural Biology
      • Synthetic & Medicinal Chemistry
      • In Vitro Biology
      • DMPK (Drug Metabolism & Pharmacokinetics)
      • In Vivo Pharmacology
      • Safety & Toxicology
      • Compound Management
    • Drug Substance Development
      • Discovery Process Chemistry
      • Process Development
      • Analytical Development
      • Process Engineering
      • Particle Science & Engineering
      • Developability & Pre-Formulation
    • Drug Substance Manufacturing
      • Product Types
      • Infrastructure
      • Engineering Technologies
    • Formulations
      • New Chemical Entity (NCE) formulation development
      • Clinical Formulation Supplies
    • New Modalities
      • Antibody–Drug Conjugates
      • Peptides
      • Oligos
  • Sustainability
    • Sustainability
    • Health, Safety and Environment
    • Corporate Social Responsibility
    • Sustainability
    • Health, Safety and Environment
    • Corporate Social Responsibility
  • Knowledge Hub
    • Newsroom
    • Blogs
    • Case Studies
    • Newsroom
    • Blogs
    • Case Studies
  • Investors
    • Investor Relations
    • Financial Information
    • Annual reports
    • Corporate Governance
    • Shareholder Services
    • Disclosures
    • Investor Relations
    • Financial Information
    • Annual reports
    • Corporate Governance
    • Shareholder Services
    • Disclosures
  • Careers
  • Contact us
  • About Us
    Main Menu
    • Overview
    • The Sai Way
    • Leadership
    • Quality
    • Facilities
      • Boston
      • Manchester
      • Hyderabad
      • Bidar
  • Our Capabilities
    Main Menu
    • Discovery
      • Integrated Drug Discovery (IDD)
      • CADD & Structural Biology
      • Synthetic & Medicinal Chemistry
      • In Vitro Biology
      • DMPK (Drug Metabolism & Pharmacokinetics)
      • In Vivo Pharmacology
      • Safety & Toxicology
      • Compound Management
    • Drug Substance Development
      • Discovery Process Chemistry
      • Process Development
      • Analytical Development
      • Process Engineering
      • Particle Science & Engineering
      • Developability & Pre-Formulation
    • Drug Substance Manufacturing
      • Product Types
      • Infrastructure
      • Engineering Technologies
    • Formulations
      • New Chemical Entity (NCE) formulation development
      • Clinical Formulation Supplies
    • New Modalities
      • Antibody–Drug Conjugates
      • Peptides
      • Oligos
  • Sustainability
    • Sustainability
    • Health, Safety and Environment
    • Corporate Social Responsibility
    • Sustainability
    • Health, Safety and Environment
    • Corporate Social Responsibility
  • Knowledge Hub
    • Newsroom
    • Blogs
    • Case Studies
    • Newsroom
    • Blogs
    • Case Studies
  • Investors
    • Investor Relations
    • Financial Information
    • Annual reports
    • Corporate Governance
    • Shareholder Services
    • Disclosures
    • Investor Relations
    • Financial Information
    • Annual reports
    • Corporate Governance
    • Shareholder Services
    • Disclosures
  • Careers
  • Contact us

Computational insights into mixing: How process engineers are leveraging simulation in multiphase systems

Mixing in a multiphase system, especially in a scale-up environment, can prove to be an uphill task. A thorough understanding of mixing patterns is crucial as it enables the optimization of process parameters, reactor design, and operational conditions. It also aids in controlling phase separations and preventing undesirable side reactions. Process engineers are leveraging simulation tools in multiphase systems to fine-tune essential parameters to achieve the first-time right scale-up and enhance process efficiency.

Solid-Liquid-Liquid Systems: A Complex Phenomenon

A solid-liquid-liquid multiphase system refers to a complex arrangement where three phases—solid, liquid, and liquid—coexist. These systems are intriguing due to their unique properties and significant impact on reaction conversions. While solid-liquid or liquid-liquid systems are more common, solid-liquid-liquid systems are relatively rare occurrences. The solid-liquid-liquid systems offer enhanced mass transfer and interfacial area, facilitating efficient chemical reactions. These systems find applications in pharmaceutical manufacturing and an understanding of the mixing dynamics in solid-liquid-liquid multiphase systems is of great significance.

Importance of Efficient Mixing

Efficient mixing plays a crucial role in promoting mass transfer and ensuring uniform distribution of reactants, thus enhancing reaction rates and conversions. It helps overcome diffusion limitations and facilitates contact between the solid particles and the reactants, leading to improved selectivity and overall process efficiency.

Initial Distribution of Solid:
https://www.dropbox.com/scl/fi/vwnsl6u6bh1o3igujis4e/Computational-insights-into-mixing-How-process-engineers-are-leveraging-simulation-in-multiphase-systems-Initial-Distribution-of-Solid.gif?rlkey=rno2a9jgxicvfmnyh7ij9uvpl&st=ghvj2f1r&dl=0

Initial Distribution of Liquid
Source: MixiT
https://www.dropbox.com/scl/fi/2o9eqi8qq8lu1df05ccwc/Computational-insights-into-mixing-How-process-engineers-are-leveraging-simulation-in-multiphase-systems-Initial-Distribution-of-Liquid.gif?rlkey=zlhd8zw55y3icqou184w8j64x&st=kw5c3sre&dl=0

Well Mixed System:
https://www.dropbox.com/scl/fi/h0dv2bjjkiqrp1uq9khre/Computational-insights-into-mixing-How-process-engineers-are-leveraging-simulation-in-multiphase-systems-Well-Mixed-System.gif?rlkey=70altivlic59ztbdbpld3j4dc&st=6afpmne5&dl=0

The ‘Scale-Up’ Challenges

In general, at the lab scale, physical observation gives a fair idea in deciding the speed of the impeller and the possibility of adjusting the speed is easy. Whereas, in a scale-up, selecting a suitable type of impeller and determining the speed of the impeller for good mixing in the plant reactor is challenging. Hence, an understanding of the minimum speed of the impeller to lift the solids to hold them in a suspension state (just suspension speed (Njs)) and the minimum speed of the impeller to disperse the less dense liquid phase into the high-dense liquid phase adequately (just dispersion speed (Njd)) is crucial for effective mass transfer as well as reaction conversion.

Computational Fluid Dynamics Simulation holds the Key

The Computational Fluid Dynamics (CFD) simulations conducted using MixIT software facilitate a comprehensive analysis of the plant reactor's mixing process.

By simulating diverse operational scenarios, engineers gain insights into the impact of impeller design, impeller speed and baffling configuration on flow behaviour and mixing efficiency. The CFD outputs provide visualization of flow patterns, allowing one to identify the homogeneous distribution of solids and uniform dispersion of the liquid phase throughout the reactor. This detailed understanding empowers us to optimize the reactor's geometry and operational parameters, leading to improved reaction kinetics and enhanced product quality. The utilization of CFD-based virtual modelling and simulation has proved instrumental in reducing costs, minimizing process development time, and ensuring efficient scale-up of the process.

Various Tools We Deploy

Sai Life Sciences utilizes a range of software tools such as MixiT, Dynochem and AspenOne to anticipate process performance under varying scales and operating conditions.

MixiT, a CFD-based simulation software, is used to optimize mixing operations in various multiphase systems by predicting critical parameters such as mixing time, power consumption, and the efficiency of mixing systems, along with velocity and flow distribution contours. Based on the output obtained from the MixiT simulation, engineers select the appropriate mixing equipment, optimize process conditions, and avoid mixing issues during scale-up. In particular, while using MixIT, engineers analyze and optimize fluid flow and heat transfer in process equipment. This enables the engineers to evaluate the effects of scale-up on fluid dynamics, identify potential obstacles, and optimize equipment selection and process conditions, leading to improved process performance.

Dynochem finds extensive application in analyzing and optimizing chemical reactions, crystallization, drying, and other unit operations. The software enables engineers to predict process performance by considering factors such as heat transfer, mass transfer, and reaction kinetics. Engineers leverage Dynochem to determine optimal process conditions, assess scale-up feasibility, troubleshoot production issues, and ensure the smooth operation of critical processes.

Aspen Plus plays a vital role in process simulation and modelling during the process development to understand the thermophysical properties of the new molecules. The software is also used to simulate the processes such as distillation, extractions and design the equipment to improve the process efficiency.

Conclusion

Through process simulation, engineers can fine-tune essential parameters to achieve the first-time right scale-up and enhance process efficiency. These tools are used during the process development to develop a robust scalable process, facilitate te

  • Sai Editorial
  • 18 Jul 2023
Link X-twitter Facebook Linkedin

Related Articles

  • Admin
  • - 3 Jun 2026

HTE: Unlocking the Potential of a Powerful Tool in Drug Discovery and Development

As an enabling technology, High Throughput Experimentation (HTE) has paved the way for the execution of large, parallel sets of experiments […]

  • Admin
  • - 13 May 2026

Dhruva – Intelligent Process Flow & Risk Evaluation Platform

Dhruva is our in-house digital application developed to automate Process Flow Diagrams (PFDs) and proactively identify potential risks associated with […]

  • Admin
  • - 13 May 2026

Contribution to ISPE Good Practice Guide: Technology Transfer

Sai Life Sciences contributed a case study to the International Society for Pharmaceutical Engineering (ISPE) Good Practice Guide: Technology Transfer […]

1 / 41234

DS-7, IKP Knowledge Park,
Turkapally Village, Shameerpet Mandal,
Medchal-Malkajgiri District-500078,
Telangana, India

Company
Main Menu
  • About Us
  • Investors
  • Careers
  • Contact us
Our Capabilities
Main Menu
  • Discovery
  • Drug Substance Development
  • Drug Substance Manufacturing
  • Formulations
  • New Modalities
Knowledge Hub
Main Menu
  • News
  • Blogs
  • Case Studies
Legal
Main Menu
  • Corporate Policies
  • Privacy Policy
  • Cookie Policy
  • Terms & Conditions

© 2026 Sai Life Sciences All rights reserved.

Facebook-f Instagram Linkedin-in X-twitter Youtube